Cefdinir dispersible tablets, the first modern pharmaceutical, passed the consistency evaluation
-
Last Update: 2020-02-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On February 5, Hyundai pharmaceutical announced that the cefdinir dispersible tablets (0.1g) of Zhijun, a state-owned subsidiary of Hyundai pharmaceutical, had passed the consistency evaluation and became the first in China Cefdinir is mainly suitable for Staphylococcus, Streptococcus, pneumococcus, Haemophilus influenzae and other strains Caused by the following infections: laryngitis, tonsillitis, acute bronchitis, pneumonia; otitis media, sinusitis; intrauterine infection, vestibular gland inflammation; mastitis, trauma or surgical wound secondary infection; folliculitis, chronic pyoderma; blepharitis, granuloma, blepharitis, etc The original product of the drug is cefdinir capsule of asteriaspharma, and the trade name is cefzon According to the data of PDB, the global sales of cefdinir in 2018 is 394 million US dollars In 2018, the sales revenue (excluding tax) of Zhijun cefdinir dispersible tablets (0.1g) was about 150 million yuan.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.